US Topical Scar Treatment Market Size, Share & Trends Analysis Report By End-use, By Scar Type (Atrophic Scars, Hypertrophic & Keloid Scars, Contracture Scars, and Stretch Marks), By Product, and Forecast, 2023 - 2030

The US Topical Scar Treatment Market size is expected to reach $7.2 Billion by 2030, rising at a market growth of 7.8% CAGR during the forecast period.

The topical scar treatment market in the United States has grown significantly recently. With the desire for flawless skin becoming more prevalent, U.S. consumers are seeking effective solutions to reduce the appearance of scars caused by injuries, surgeries, acne, or other skin conditions. One of the key drivers of the topical scar treatment market is the growing demand for non-invasive scar management options. Americans are increasingly preferring topical treatments over invasive procedures such as surgery or laser therapy due to their convenience, affordability, and lower risk of side effects.

Furthermore, the rise in cosmetic procedures and surgeries has expanded the topical scar treatment market. Procedures such as plastic surgery, dermatological surgeries, and minimally invasive cosmetic treatments often result in scarring, prompting the need for effective scar management solutions. According to the National Library of Medicine, interest in cosmetic surgical procedures in the United States has steadily increased. The American Society of Plastic Surgeons (ASPS) reported that its members performed 15,595,955 cosmetic surgical procedures in 2020. Of these procedures, 92% were conducted on female patients. This surge in cosmetic procedures underscores a growing demand for advanced solutions, including those targeting scar treatment, within the U.S.

However, the COVID-19 pandemic has profoundly impacted the topical scar treatment market in the United States. The outbreak of the virus led to disruptions in the healthcare system, with elective procedures being postponed or canceled to prioritize resources for COVID-19 patients. As a result, the demand for topical scar treatments experienced a temporary decline, particularly in clinics and aesthetic centers where these treatments are commonly offered. Many Americans have also been confined to their homes due to lockdowns and social distancing measures, reducing the need for cosmetic procedures and scar management treatments.

Market Trends

Rising demand for treatment for cutaneous scarring

In recent years, the topical scar treatment market in the United States has witnessed a concerning rise in cases of cutaneous scarring. Cutaneous scarring refers to the formation of abnormal or excessive scars on the skin, often resulting from injury, surgery, or various dermatological conditions. This increase in cutaneous scarring has raised significant concerns among healthcare professionals and patients alike, prompting a closer examination of the factors contributing to this trend.

One potential factor contributing to the rise in cutaneous scarring is the growing popularity of topical scar treatments among U.S. consumers. With an array of over-the-counter creams, gels, and ointments readily available in the industry, many individuals seek out these products to minimize the appearance of scars. According to the National Library of Medicine, the increasing prevalence of cutaneous scarring has led to a notable surge in demand for topical scar treatment market in the U.S. This rise is fueled by both the psychological and physiological challenges faced by American patients, prompting significant investments totaling an estimated $12 billion annually towards scar treatments.

Moreover, healthcare providers and researchers in the U.S. are exploring innovative interventions to optimize scar management outcomes. This includes developing advanced wound care products, such as silicone-based gel sheets, pressure garments, and topical formulations containing active ingredients like silicone, onion extract, and vitamin E, which have demonstrated efficacy in minimizing scar hypertrophy and improving skin texture. Hence, the rise in cutaneous scarring cases in the United States underscores the need for enhanced research and innovation in scar management strategies and topical treatments.

Growing incidence of skin injuries

The topical scar treatment market in the U.S. has witnessed a concerning trend with a rising incidence of skin injuries associated with various scar treatment products. One of the primary factors contributing to this uptick in skin injuries is the proliferation of low-quality or counterfeit products in the industry. With the increasing demand for scar treatment solutions, especially in a society that places a premium on flawless skin, unscrupulous manufacturers have flooded the industry with substandard products that often contain harsh chemicals or unregulated ingredients. These products promise quick results but end up causing irritation, allergic reactions, and even exacerbate existing skin conditions.

Moreover, inadequate regulation and oversight in the topical scar treatment market have allowed such products to thrive unchecked. Many Americans are unaware of the potential risks of using these products and may fall victim to misleading advertising or insufficient labeling. Another contributing factor is the need for proper guidance and supervision from healthcare professionals.

While some scar treatment products are available over the counter, others require a prescription or should only be administered under medical supervision. U.S. consumers misuse these products without proper guidance, leading to adverse reactions and skin injuries. To address this growing concern, concerted efforts are needed from regulatory authorities, healthcare professionals, and consumers. Thus, safeguarding the public from substandard scar treatment products necessitates collaborative action from regulatory agencies, healthcare providers, and informed U.S. consumers.

Competition Analysis

In the United States, the topical scar treatment market is diverse and dynamic, with several companies vying to address the needs of consumers seeking solutions for scar management. One prominent U.S. topical scar treatment market player is Johnson & Johnson, a global healthcare conglomerate with a significant presence in consumer health. Through its subsidiary, Johnson & Johnson Consumer Inc., the company offers scar treatment products under brands like Neosporin and Aveeno. These products often combine active ingredients such as silicone, aloe vera, and vitamin E to help reduce the visibility of scars and improve skin texture.

Another major player in the topical scar treatment market is Mederma, owned by Merz Pharmaceuticals, LLC. Mederma specializes in scar management products, including gels and creams formulated to minimize the appearance of scars. The brand's offerings often feature proprietary ingredients like Cepalin, a botanical extract believed to promote healing and improve scar texture. The company's products are widely available in retail outlets across the U.S. and are commonly recommended by healthcare professionals for scar treatment.

Smith & Nephew plc, a multinational medical equipment manufacturing company, also holds a significant share of the U.S. topical scar treatment market. While primarily known for its advanced wound care products, Smith & Nephew offers scar management solutions tailored to healthcare settings. These include silicone-based dressings or topical preparations designed to facilitate scar healing and minimize discomfort for patients recovering from surgery or traumatic injuries.

In recent years, smaller companies specializing in skincare innovation have emerged as key players in the topical scar treatment market. For example, Stratpharma AG, a Swiss-based biotech company, has gained traction with its advanced scar therapy products. Stratpharma's portfolio includes silicone-based gels and films designed to effectively manage scars resulting from surgery, burns, or other injuries. These products are backed by clinical research and are available through healthcare professionals and online retailers in the U.S.

Additionally, emerging brands like ScarAway have carved out a niche in the U.S. topical scar treatment market by offering innovative solutions for at-home use. ScarAway's product line encompasses silicone sheets, gels, and tapes designed for easy application and long-term scar management. These products cater to consumers seeking convenient, affordable options for addressing scars without medical intervention. As consumer demand for effective and accessible scar solutions persists, the landscape of the topical scar treatment market in the U.S. is likely to evolve, with competition driving innovation and expanding options for individuals seeking to improve the appearance of their scars.

List of Key Companies Profiled

• Smith & Nephew PLC
• Lumenis Be Ltd.
• Merz Pharma GmbH & Co. KGaA
• Sonoma Pharmaceuticals, Inc.
• Molnlycke Health Care AB
• Suneva Medical, Inc.
• Perrigo Company PLC
• Cynosure, LLC (Clayton, Dubilier & Rice, LLC)
• Newmedical Technology Inc.
• Integra LifeSciences Holdings Corporation

US Topical Scar Treatment Market Report Segmentation

By End-use

• Hospitals
• Clinics
• Homecare

By Scar Type

• Atrophic Scars
• Hypertrophic & Keloid Scars
• Contracture Scars
• Stretch Marks

By Product

• Creams
• Gels
• Silicon Sheets
• Others

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 US Topical Scar Treatment Market, by End-use
1.4.2 US Topical Scar Treatment Market, by Scar Type
1.4.3 US Topical Scar Treatment Market, by Product
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Opportunities
2.2.3 Market Restraints
2.2.4 Market Challenges
2.2.5 Market Trends
2.3 Porter’s Five Forces Analysis

Chapter 3. US Topical Scar Treatment Market
3.1 US Topical Scar Treatment Market by End-use
3.2 US Topical Scar Treatment Market by Scar Type
3.3 US Topical Scar Treatment Market by Product

Chapter 4. Company Profiles – Global Leaders
4.1 Smith & Nephew PLC
4.1.1 Company Overview
4.1.2 Financial Analysis
4.1.3 Regional and Segmental Analysis
4.1.4 Research & Development Expense
4.1.5 SWOT Analysis
4.2 Lumenis Be Ltd.
4.2.1 Company Overview
4.2.2 Recent strategies and developments:
4.2.2.1 Partnerships, Collaborations, and Agreements:
4.2.2.2 Product Launches and Product Expansions:
4.2.3 SWOT Analysis
4.3 Merz Pharma GmbH & Co. KGaA
4.3.1 Company Overview
4.3.2 Recent strategies and developments:
4.3.2.1 Partnerships, Collaborations, and Agreements:
4.3.3 SWOT Analysis
4.4 Sonoma Pharmaceuticals, Inc.
4.4.1 Company Overview
4.4.2 Financial Analysis
4.4.3 Regional Analysis
4.4.4 Research & Development Expenses
4.4.5 Recent strategies and developments:
4.4.5.1 Product Launches and Product Expansions:
4.4.6 SWOT Analysis
4.5 Molnlycke Health Care AB
4.5.1 Company Overview
4.5.2 SWOT Analysis
4.6 Suneva Medical, Inc.
4.6.1 Company Overview
4.6.2 Recent strategies and developments:
4.6.2.1 Product Launches and Product Expansions:
4.6.3 SWOT Analysis
4.7 Perrigo Company PLC
4.7.1 Company Overview
4.7.2 Financial Analysis
4.7.3 Segmental and Regional Analysis
4.7.4 Research & Development Expenses
4.7.5 SWOT Analysis
4.8 Cynosure, LLC (Clayton, Dubilier & Rice, LLC)
4.8.1 Company Overview
4.8.2 Recent strategies and developments:
4.8.2.1 Partnerships, Collaborations, and Agreements:
4.8.2.2 Product Launches and Product Expansions:
4.8.3 SWOT Analysis
4.9 Newmedical Technology Inc.
4.9.1 Company Overview
4.9.2 SWOT Analysis
4.10. Integra LifeSciences Holdings Corporation
4.10.1 Company Overview
4.10.2 Financial Analysis
4.10.3 Segmental and Regional Analysis
4.10.4 Research & Development Expenses
4.10.5 SWOT Analysis

TABLE 1 US Topical Scar Treatment Market, 2019 - 2022, USD Million
TABLE 2 US Topical Scar Treatment Market, 2023 - 2030, USD Million
TABLE 3 US Topical Scar Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 4 US Topical Scar Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 5 US Topical Scar Treatment Market by Scar Type, 2019 - 2022, USD Million
TABLE 6 US Topical Scar Treatment Market by Scar Type, 2023 - 2030, USD Million
TABLE 7 US Topical Scar Treatment Market by Product, 2019 - 2022, USD Million
TABLE 8 US Topical Scar Treatment Market by Product, 2023 - 2030, USD Million
TABLE 9 Key Information – Smith & Nephew PLC
TABLE 10 key Information – Lumenis Be Ltd.
TABLE 11 Key information – Merz Pharma GmbH & Co. KGaA
TABLE 12 Key Information – Sonoma Pharmaceuticals, Inc.
TABLE 13 Key Information – Molnlycke Health Care AB
TABLE 14 Key Information – Suneva Medical, Inc.
TABLE 15 Key Information – Perrigo Company PLC
TABLE 16 Key Information – Cynosure, LLC
TABLE 17 Key Information – Newmedical Technology Inc.
TABLE 18 Key Information – Integra LifeSciences Holdings Corporation

List of Figures
FIG 1 Methodology for the research
FIG 2 US Topical Scar Treatment Market, 2019 - 2022, USD Million
FIG 3 Key Factors Impacting Topical Scar Treatment Market
FIG 4 Porter’s Five Forces Analysis - Topical Scar Treatment Market
FIG 5 US Topical Scar Treatment Market share by End-use, 2022
FIG 6 US Topical Scar Treatment Market share by End-use, 2030
FIG 7 US Topical Scar Treatment Market by End-use, 2019 - 2030, USD Million
FIG 8 US Topical Scar Treatment Market share by Scar Type, 2022
FIG 9 US Topical Scar Treatment Market share by Scar Type, 2030
FIG 10 US Topical Scar Treatment Market by Scar Type, 2019 - 2030, USD Million
FIG 11 US Topical Scar Treatment Market share by Product, 2022
FIG 12 US Topical Scar Treatment Market share by Product, 2030
FIG 13 US Topical Scar Treatment Market by Product, 2019 - 2030, USD Million
FIG 14 SWOT Analysis: Smith & Nephew PLC
FIG 15 SWOT Analysis: Lumenis Be Ltd
FIG 16 SWOT Analysis: Merz Pharma GmbH & Co. KGaA
FIG 17 SWOT Analysis: Sonoma Pharmaceuticals, Inc.
FIG 18 Swot Analysis: Molnlycke Health Care AB
FIG 19 Swot Analysis: Suneva Medical, Inc.
FIG 20 SWOT Analysis: Perrigo Company PLC
FIG 21 Swot Analysis: CYNOSURE, LLC
FIG 22 Swot Analysis: Newmedical Technology Inc.
FIG 23 SWOT Analysis: Integra LifeSciences Holdings Corporation